Advanced in Hemoglobin SC Disease
Advanced in Hemoglobin SC Disease
University Hospitals Medical Group, Inc.
11100 Euclid Ave, 
Cleveland, OH 

Overview

Samuel Anim is a Pediatric Hematologist Oncology provider in Cleveland, Ohio. Dr. Anim is rated as an Advanced provider by MediFind in the treatment of Hemoglobin SC Disease. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemoglobin SC Disease, Hemoglobin C Disease, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 31 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in MI
Hospital Affiliations
Uh Cleveland Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Mutual
  • HMO
  • PPO
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Sanford Health
  • HMO
  • PPO
SummaCare
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

UNIVERSITY HOSPITALS MEDICAL GROUP INC
11100 Euclid Ave, Cleveland, OH 44106

Additional Areas of Focus

Dr. Anim has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


31 Clinical Trials

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
View 27 Less Clinical Trials
Similar Doctors
Advanced in Hemoglobin SC Disease
Pediatric Hematology Oncology
Advanced in Hemoglobin SC Disease
Pediatric Hematology Oncology
11100 Euclid Ave, 
Cleveland, OH 
 (0.1 miles away)
Languages Spoken:
English

Amma Owusu is a Pediatric Hematologist Oncology provider in Cleveland, Ohio. Dr. Owusu is rated as a Distinguished provider by MediFind in the treatment of Hemoglobin SC Disease. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Hemoglobinopathy.

Advanced in Hemoglobin SC Disease
Pediatric Hematology Oncology
Advanced in Hemoglobin SC Disease
Pediatric Hematology Oncology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.8 miles away)
Languages Spoken:
English

Crawford Strunk is a Pediatric Hematologist Oncology provider in Cleveland, Ohio. Dr. Strunk is rated as an Advanced provider by MediFind in the treatment of Hemoglobin SC Disease. His top areas of expertise are Sickle Cell Disease, Hemoglobinopathy, Hemoglobin SC Disease, and Congenital Hemolytic Anemia.

Experienced in Hemoglobin SC Disease
Pediatric Hematology Oncology
Experienced in Hemoglobin SC Disease
Pediatric Hematology Oncology

Cleveland Clinic

9500 Euclid Ave, 
Cleveland, OH 
 (0.8 miles away)
Languages Spoken:
English

Stacey Zahler is a Pediatric Hematologist Oncology provider in Cleveland, Ohio. Dr. Zahler is rated as an Advanced provider by MediFind in the treatment of Hemoglobin SC Disease. Her top areas of expertise are Neuroblastoma, Hereditary Neuroblastoma, Hereditary Retinoblastoma, Retinoblastoma, and Bone Marrow Transplant.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Anim's expertise for a condition
ConditionClose
    View All 13 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile